{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:53:31Z","timestamp":1776992011584,"version":"3.51.4"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi241093-4\"><jats:title>Importance<\/jats:title><jats:p>Patients who have been treated for high-grade cervical intraepithelial neoplasia (CIN grade \u22652) are at a high risk for subsequent CIN and other cancers and diseases related to human papillomavirus (HPV). HPV vaccination can reduce the risk of subsequent disease in patients surgically treated for grade 2 or greater CIN; however, there is no formal recommendation for prophylactic HPV vaccination in this high-risk population, and the cost-effectiveness is unknown.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241093-5\"><jats:title>Objective<\/jats:title><jats:p>To assess the incremental lifetime outcomes, costs, and cost-effectiveness of integrating peritreatment 9-valent HPV (9vHPV) vaccination in combination with posttreatment surveillance for the prevention of cervical cancer and other HPV-attributable diseases in patients surgically treated for grade 2 or greater CIN vs posttreatment surveillance alone from a UK payer perspective.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241093-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This economic evaluation used 3 independent Markov model structures. Model inputs for vaccine efficacy, utilities, and costs were obtained from published sources, and cervical cancer screening data were obtained from the National Health Service Cervical Screening Program. Costs were adjusted to 2022 to 2023 reference years. Data were analyzed from October 2022 to September 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241093-7\"><jats:title>Exposure<\/jats:title><jats:p>Peritreatment vaccination with 9vHPV in combination with posttreatment surveillance compared with posttreatment surveillance alone.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241093-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Clinical outcomes included grade 1, 2, or 3 CIN; cervical cancer; vaginal cancer; vulvar cancer; anal cancer; head and neck cancer; genital warts; and recurrent respiratory papillomatosis. Incremental cost-effectiveness ratios (ICERs) using a willingness-to-pay threshold (WTP) of \u00a320\u202f000 (US $26\u202f200) per quality-adjusted life-year (QALY) were estimated. Deterministic sensitivity analysis and probabilistic sensitivity analysis were performed.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241093-9\"><jats:title>Results<\/jats:title><jats:p>Vaccination with 9vHPV in conjunction with posttreatment surveillance was cost-effective, with a favorable ICER of \u00a313\u202f789.07 (US $18\u202f064.68) per QALY gained (ie, below the WTP of \u00a320\u202f000 per QALY) vs posttreatment surveillance alone. The resulting ICER was \u00a352\u202f358.01 (US $68\u202f588.99) per HPV-related cancer averted and \u00a364\u202f090 (US $83\u202f958.18) per HPV-related cancer death averted. The ICER was most sensitive to discount rate, incidence of HPV infection, vaccine price, and age at initial treatment for grade 2 or greater CIN. Results of the probabilistic sensitivity analysis showed peritreatment 9vHPV vaccination was cost-effective at the WTP recommended by the UK\u2019s Joint Committee on Vaccination and Immunisation (90% of iterations &amp;amp;lt;\u00a330\u202f000 [US $39\u202f300] per QALY) in 100% of iterations.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241093-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>These findings suggest that peritreatment prophylactic 9vHPV vaccination is a cost-effective option for preventing subsequent HPV-attributable diseases in patients surgically treated for grade 2 or greater CIN.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.37703","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T15:31:10Z","timestamp":1728055870000},"page":"e2437703","source":"Crossref","is-referenced-by-count":6,"title":["Cost-Effectiveness of 9-Valent HPV Vaccination for Patients Treated for High-Grade Cervical Intraepithelial Neoplasia in the UK"],"prefix":"10.1001","volume":"7","author":[{"given":"Alhaji","family":"Cherif","sequence":"first","affiliation":[{"name":"Merck & Co Inc, Rahway, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Ovcinnikova","sequence":"additional","affiliation":[{"name":"MSD (UK) Limited, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cody","family":"Palmer","sequence":"additional","affiliation":[{"name":"Merck & Co Inc, Rahway, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla","family":"Engelbrecht","sequence":"additional","affiliation":[{"name":"MSD (UK) Limited, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Reuschenbach","sequence":"additional","affiliation":[{"name":"MSD Sharpe and Dohme GmBH, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Daniels","sequence":"additional","affiliation":[{"name":"Merck & Co Inc, Rahway, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"issue":"2","key":"zoi241093r1","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"10316","key":"zoi241093r3","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"zoi241093r4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/pathogens12020298","article-title":"HPV and cervical cancer: a review of epidemiology and screening uptake in the UK.","volume":"12","author":"Choi","year":"2023","journal-title":"Pathogens"},{"issue":"6","key":"zoi241093r5","doi-asserted-by":"publisher","first-page":"656.e1","DOI":"10.1016\/j.ajog.2023.08.008","article-title":"Clinical course of cervical intraepithelial neoplasia grade 2: a population-based cohort study.","volume":"229","author":"Lycke","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"zoi241093r6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e6855","article-title":"Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study.","volume":"345","author":"Rebolj","year":"2012","journal-title":"BMJ"},{"issue":"7629","key":"zoi241093r7","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/bmj.39363.471806.BE","article-title":"Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study.","volume":"335","author":"Strander","year":"2007","journal-title":"BMJ"},{"issue":"2","key":"zoi241093r8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ygyno.2020.01.030","article-title":"Risk of vulvar, vaginal and anal high-grade intraepithelial neoplasia and cancer according to cervical human papillomavirus (HPV) status: a population-based prospective cohort study.","volume":"157","author":"Bertoli","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"2","key":"zoi241093r9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.annonc.2019.11.004","article-title":"Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature.","volume":"31","author":"Kalliala","year":"2020","journal-title":"Ann Oncol"},{"issue":"42","key":"zoi241093r10","doi-asserted-by":"publisher","first-page":"6194","DOI":"10.1016\/j.vaccine.2023.08.047","article-title":"Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer.","volume":"41","author":"Reuschenbach","year":"2023","journal-title":"Vaccine"},{"issue":"5","key":"zoi241093r11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S1470-2045(11)70078-X","article-title":"Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study.","volume":"12","author":"Kocken","year":"2011","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi241093r12","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1002\/ijc.21604","article-title":"Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia.","volume":"118","author":"Soutter","year":"2006","journal-title":"Int J Cancer"},{"issue":"10","key":"zoi241093r13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/jnci\/djp089","article-title":"Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study.","volume":"101","author":"Melnikow","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"zoi241093r14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1136\/sextrans-2023-055793","article-title":"Timing of HPV vaccination as adjuvant treatment of CIN2+ recurrence in women undergoing surgical excision: a meta-analysis and meta-regression.","volume":"99","author":"Petr\u00e1\u0161","year":"2023","journal-title":"Sex Transm Infect"},{"key":"zoi241093r15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070135","article-title":"Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis.","volume":"378","author":"Kechagias","year":"2022","journal-title":"BMJ"},{"issue":"41","key":"zoi241093r16","doi-asserted-by":"publisher","first-page":"6402","DOI":"10.1016\/j.vaccine.2020.07.055","article-title":"Prophylactic HPV vaccination after conization: A systematic review and meta-analysis.","volume":"38","author":"Jentschke","year":"2020","journal-title":"Vaccine"},{"key":"zoi241093r17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1119566","article-title":"Vaccinating women previously treated for human papillomavirus-related cervical precancerous lesions is highly cost-effective in China.","volume":"14","author":"Zou","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"zoi241093r18","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/AOG.0000000000005106","article-title":"Adjuvant human papillomavirus vaccination after excisional procedure for cervical intraepithelial neoplasia: a cost-effectiveness analysis.","volume":"141","author":"Chaiken","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"5","key":"zoi241093r22","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/0272989X12455463","article-title":"State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3.","volume":"32","author":"Siebert","year":"2012","journal-title":"Med Decis Making"},{"issue":"6","key":"zoi241093r23","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jval.2012.04.013","article-title":"Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4.","volume":"15","author":"Karnon","year":"2012","journal-title":"Value Health"},{"issue":"3","key":"zoi241093r24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/LGT.0000000000000604","article-title":"The natural history of cervical intraepithelial neoplasia grades 1, 2, and 3: a systematic review and meta-analysis.","volume":"25","author":"Loopik","year":"2021","journal-title":"J Low Genit Tract Dis"},{"issue":"9","key":"zoi241093r25","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.3390\/vaccines10091543","article-title":"Human papillomavirus vaccine impact and effectiveness in six high-risk populations: a systematic literature review.","volume":"10","author":"Goodman","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"zoi241093r26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"issue":"9574","key":"zoi241093r27","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"issue":"9576","key":"zoi241093r28","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"issue":"19","key":"zoi241093r29","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"17","key":"zoi241093r30","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi241093r34","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.","volume":"356","author":"FUTURE II Study Group","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi241093r35","doi-asserted-by":"publisher","first-page":"e1335","DOI":"10.1016\/S2214-109X(20)30277-1","article-title":"Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis.","volume":"8","author":"Zou","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"9","key":"zoi241093r36","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/infdis\/jiv753","article-title":"Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis.","volume":"213","author":"Beachler","year":"2016","journal-title":"J Infect Dis"},{"issue":"1","key":"zoi241093r37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/infdis\/jiy112","article-title":"Risk of HPV-16\/18 infections and associated cervical abnormalities in women seropositive for naturally acquired antibodies: pooled analysis based on control arms of two large clinical trials.","volume":"218","author":"Safaeian","year":"2018","journal-title":"J Infect Dis"},{"issue":"10","key":"zoi241093r38","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1002\/cam4.1879","article-title":"Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16\/18 antibodies.","volume":"8","author":"Rosillon","year":"2019","journal-title":"Cancer Med"},{"issue":"9","key":"zoi241093r39","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/ijc.31202","article-title":"Long-term risk of cervical cancer following conization of cervical intraepithelial neoplasia grade 3-A Danish nationwide cohort study.","volume":"142","author":"Sand","year":"2018","journal-title":"Int J Cancer"},{"issue":"22","key":"zoi241093r40","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1200\/JCO.2016.71.4543","article-title":"Long-lasting increased risk of human papillomavirus-related carcinomas and premalignancies after cervical intraepithelial neoplasia grade 3: a population-based cohort study.","volume":"35","author":"Ebisch","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi241093r41","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/ijc.32834","article-title":"The relative risk of noncervical high-risk human papillomavirus-related (pre)malignancies after recurrent cervical intraepithelial neoplasia grade 3: a population-based study.","volume":"147","author":"Loopik","year":"2020","journal-title":"Int J Cancer"},{"key":"zoi241093r2","unstructured":"Cancer Research UK. Cervical cancer statistics. Accessed November 10, 2023. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/cervical-cancer"},{"key":"zoi241093r19","unstructured":"Nonavalent prophylactic HPV vaccine (GARDASIL9) after local conservative the NOVEL Trial (NOVEL). Accessed July 4, 2024. https:\/\/clinicaltrials.gov\/study\/NCT03979014"},{"key":"zoi241093r20","unstructured":"NHS England. NHS urges more women to take up cervical screening invitations. News release. June 22, 2024. Accessed July 4, 2024. https:\/\/www.england.nhs.uk\/2024\/06\/nhs-urges-more-women-to-take-up-cervical-screening-invitations\/"},{"key":"zoi241093r21","unstructured":"Public Health England. Accredited official statistics: cervical screening programme\u2014England, 2020-21. Accessed July 4, 2024. https:\/\/www.gov.uk\/government\/statistics\/cervical-screening-programme-england-2020-21"},{"key":"zoi241093r31","unstructured":"Personal Social Services Research Unit. Unit costs of health and social care: inflation indices. Accessed July 2, 2024. https:\/\/www.pssru.ac.uk\/pub\/uc\/uc2021\/sourcesofinformation.pdf"},{"key":"zoi241093r32","unstructured":"Joint Committee on Vaccination and Immunisation. Code of Practice June 2013. Accessed July 2, 2024. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/224864\/JCVI_Code_of_Practice_revision_2013_-_final.pdf"},{"key":"zoi241093r33","unstructured":"Joint Committee on Vaccination and Immunisation. Statement on HPV vaccination. Accessed February 20, 2020. https:\/\/assets.publishing.service.gov.uk\/media\/5b4e0a34e5274a73119d7614\/JCVI_Statement_on_HPV_vaccination_2018.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2824380\/cherif_2024_oi_241093_1727454023.8727.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T15:31:18Z","timestamp":1728055878000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2824380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.37703","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]}}}